Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Conroy Kevin T reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Kevin T. Conroy received a grant of 2,286 common shares in the form of restricted stock units. These units were awarded under the Abbott Laboratories 2026 Incentive Stock Program as compensation, not through an open-market purchase.
The award will be settled one-for-one in Abbott common shares upon the earlier of his separation from service, death, or a change in control as defined in the program. After this grant, Conroy directly holds 133,737 Abbott common shares.
ABBOTT LABORATORIES director Kevin T. Conroy filed an initial Form 3 reporting his equity stake following Abbott’s acquisition of Exact Sciences. He reports direct beneficial ownership of 131,451 common shares without par value. This position primarily reflects restricted stock units that accelerated upon Exact’s change in control at the merger’s effective time.
Under the merger completed on March 23, 2026, each share of Exact common stock was converted into the right to receive $105.00 in cash, without interest, subject to withholding taxes. Certain Exact restricted stock units were assumed by Abbott and converted into Abbott restricted stock unit awards based on the merger consideration and the 10‑day average Abbott share price. The reported RSU award fully accelerated at separation; one quarter was settled immediately, and the remaining three quarters will be settled in shares six months and one day after the effective time, with an option to have shares withheld for taxes.
Stratton John G reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director John G. Stratton received an award covering 2,286 common shares as a grant of restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program. Following this award, he holds 21,319 common shares directly.
The award will be settled in Abbott common shares on a one-to-one basis upon the earlier of the director’s separation from service, death, or a change in control as defined in the program. This is a compensation-related equity grant rather than an open-market share purchase.
ABBOTT LABORATORIES director Daniel J. Starks bought additional company stock and received new equity awards. He made an open-market purchase of 10,000 common shares at an average price of $92.6537 per share, bringing his direct holding to 6,751,103 common shares.
Starks also received a grant of 2,286 restricted stock units under Abbott’s 2026 Incentive Stock Program, payable one-for-one in common shares upon separation from service, death, or a change in control. In addition, he was granted stock options for 7,105 common shares at an exercise price of $91.86 per share, expiring in 2036. Separately, 258 common shares are held indirectly in the Alynne Starks 2012 Irrevocable Trust, for which he is the sole trustee.
ABBOTT LABORATORIES director Michael F. Roman received an equity award covering 2,286 common shares. The Form 4 shows this as a grant or award acquisition at a stated price of $0.00 per share, bringing his directly held stake to 10,764 common shares after the transaction.
The footnote explains this is a restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program. The units will convert one-for-one into Abbott common shares upon the earlier of his separation from service, death, or a change in control as defined in the program.
ABBOTT LABORATORIES director Michael O’Grady reported equity awards under the company’s 2026 Incentive Stock Program. He was granted 2,286 restricted stock units, each convertible into one Abbott common share upon separation from service, death, or a change in control as defined in the program.
He also received an option to buy 5,929 Abbott common shares at an exercise price of $91.86 per share, expiring on April 23, 2036, in a transaction exempt from Section 16 under Rule 16b-3. Following these awards, his direct holdings of Abbott common shares reported in this filing total 7,603 shares.
Abbott Laboratories director Nancy McKinstry reported equity awards rather than open-market trades. She received 2,286 restricted stock units that will convert one-for-one into common shares upon separation from service, death, or a change in control under Abbott’s 2026 Incentive Stock Program.
She also received options for 2,305 common shares at an exercise price of $91.86 per share, expiring in 2036. Following these awards, she directly holds 41,010 common shares and 2,305 options.
McDew Darren W reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Darren W. McDew received an equity award of 2,286 common shares-equivalent on a grant/award basis. The award is structured as a restricted stock unit grant under the Abbott Laboratories 2026 Incentive Stock Program and carries no cash purchase price.
The award will be settled in Abbott common shares on a one-to-one basis upon the earlier of his separation from service, death, or a change in control as defined in the program. After this grant, McDew directly holds 12,678 common shares, reflecting routine director compensation rather than an open-market share purchase.
Kumbier Michelle reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Michelle Kumbier received a grant of 2,286 restricted stock units. The award was made in the form of common shares without par value at no purchase price and is part of Abbott’s 2026 Incentive Stock Program.
The restricted stock units will be paid in Abbott common shares on a one-to-one basis upon the earlier of Kumbier’s separation from service, death, or a change in control as defined in the program. Following this grant, she directly holds 18,000 Abbott common shares.
Abbott Laboratories director Patricia Paola Gonzalez received an equity award tied to 2,286 common shares. The Form 4 shows an acquisition coded as a grant or award, with no cash price per share, reflecting stock-based compensation rather than an open-market purchase.
According to the footnote, this is a restricted stock unit award under the Abbott Laboratories 2026 Incentive Stock Program and will be paid in Abbott common shares on a one-to-one basis upon the earlier of the director’s separation from service, death, or a change in control as defined in the program. Following this award, Gonzalez directly holds 9,205 common shares.